[Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
OBJECTIVE
To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN).


METHODS
Three patients with CIN were treated with topical MMC 0.02%. Our follow-up period was twelve months (range 8-18 months).


RESULTS
CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture.


CONCLUSIONS
Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.
Ramos-López
J F
JF
Hospital Universitario La Fe y Fundación Oftalmológica del Mediterráneo (FOM), Valencia, España. juanframos@oftalmogranada.com
Martínez-Costa Pérez
R
R
Cisneros Lanuza
A L
AL
Francés Muñoz
E
E
Monte Boque
E
E
Muñoz Gómez
M C
MC
López-Sánchez
E V
EV
Menezo Rozalén
J L
JL
D000287:Administration, Topical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin